The PDL1/PD1 axis is a promising target because immune checkpoint inhibitors against PDL1/PD1 have shown great results as an anti-cancer treatment, and there is an urgent need to develop radioligands targeting PDL1/PD1 to select potential responders. This evidence concerns the gene CD274 and cancer.